RenovoRx's Breakthrough: Abstract Accepted for ASCO Gastrointestinal Cancers Symposium 2025
Wednesday, Jan 8, 2025 8:29 am ET
RenovoRx, Inc. (Nasdaq: RNXT), a life sciences company developing novel targeted oncology therapies, has announced the acceptance of an abstract for presentation at the upcoming ASCO Gastrointestinal Cancers Symposium 2025. This significant development highlights the company's innovative Trans-Arterial Micro-Perfusion (TAMP™) therapy platform and its potential to revolutionize the treatment of gastrointestinal cancers.

The abstract, titled "Targeted Intra-Arterial Chemotherapy for Locally Advanced Pancreatic Cancer: Results from the TIGeR-PaC Phase III Trial," focuses on the company's lead product candidate, RenovoGem™. This novel oncology drug-device combination product utilizes the FDA-cleared RenovoCath® delivery platform to administer gemcitabine chemotherapy directly to tumor sites via intra-arterial administration. The TIGeR-PaC Phase III trial is a randomized, multi-center study comparing the efficacy and safety of RenovoGem versus systemic intravenous administration of gemcitabine and nab-paclitaxel in patients with locally advanced pancreatic cancer (LAPC).
The abstract presentation at the ASCO Gastrointestinal Cancers Symposium 2025 will provide an opportunity for RenovoRx to showcase its innovative TAMP therapy platform and share the latest data from the TIGeR-PaC Phase III trial. The symposium, scheduled for April 17, 2023, in Orlando, Florida, is a prestigious event that brings together leading experts in the field of gastrointestinal cancers to discuss the latest research and advancements in treatment options.
RenovoRx's TAMP therapy platform offers a targeted approach to cancer treatment, enabling physicians to isolate segments of the vascular anatomy closest to tumors and ensure precise therapeutic delivery. This targeted approach has the potential to increase safety, tolerance, and improved efficacy compared to systemic intravenous therapies. The company's ongoing clinical trials and research have demonstrated promising results, including a 65% reduction in adverse events and a 6-month median overall survival benefit for patients treated with RenovoGem.

In addition to the ASCO Gastrointestinal Cancers Symposium 2025, RenovoRx has had three abstracts accepted for presentation at major industry conferences, including ASCO GI 2025, SIO 2025, and SSO 2025. These presentations will highlight the company's novel approach to targeted oncology therapies and its potential to improve patient outcomes and quality of life.
As RenovoRx continues to advance its TIGeR-PaC Phase III trial and explore new commercial and clinical business development opportunities, investors should keep a close eye on the company's progress. The acceptance of abstracts for presentation at prestigious industry conferences, such as the ASCO Gastrointestinal Cancers Symposium 2025, serves as a testament to the company's scientific credibility and potential for future growth.
In conclusion, RenovoRx's acceptance of an abstract for presentation at the ASCO Gastrointestinal Cancers Symposium 2025 is a significant milestone for the company and its innovative TAMP therapy platform. As the company continues to advance its clinical trials and research, investors should remain optimistic about the potential for RenovoRx to revolutionize the treatment of gastrointestinal cancers and create value for shareholders.